Table 3.
Group | N | Pre-rituximab | Post-rituximab | p value | ||
---|---|---|---|---|---|---|
Relapses | Relapses | |||||
Events | ARR (95% CI) | Events | ARR (95% CI) | |||
Total | 37 | 50 | 0.366 (0.271–0.483) | 26 | 0.136 (0.088–0.201) | <0.001 |
AQP-4-IgG-positive | 27 | 38 | 0.375 (0.264–0.517) | 15 | 0.097 (0.053–0.163) | <0.001 |
Seronegative with patient 26 | 10 | 12 | 0.339 (0.175–0.592) | 11 | 0.278 (0.139–0.497) | 0.432 |
Seronegative without patient 26 | 9 | 11 | 0.314 (0.157–0.562) | 5 | 0.133 (0.043–0.311) | 0.313 |